Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Deerfield Management

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 89
Average round size
The average size of a deal this fund participated in
Portfolio companies 73
Rounds per year 3.18
Lead investments 11
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 26
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Pharmaceutical
  • Therapeutics

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Deerfield Management:
Typical Co-investors
Deerfield Management is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Deerfield Management:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Angola Capital -
Boyser SRL Barcelona, Catalonia, Spain
Brain Corp California, San Diego, United States
Brama One Ventures Indonesia, Jawa Timur, Surabaya
CG Health Ventures Barcelona, Catalonia, Spain
Changchun UP Optotech Co., Ltd. Changchun, China, Jilin
Chasestone Capital China, Shanghai
Groupon Chicago, Illinois, United States
Hedge Fund -
IDEA Fund Partners Durham, North Carolina, United States
Inter Invest Capital France, Ile-de-France, Paris
NIH Surgery -
Pengfeng Rongcheng Capital -
Reliance Industries India, Maharashtra, Mumbai
Sport & Performance Capital -
Supreme Group Dubai, United Arab Emirates
Tibet Kunwu Jiuding Investment Management Chengguan District, China, Lhasa
VivaKi Chicago, Illinois, United States
Woodland Venture Fund New York, Roslyn, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Insilico Medicine

Artificial Intelligence
Health Care
$60M06 Jun 2022 Hong Kong Island, Hong Kong, China

Epic Sciences

Health Care
Health Diagnostics
$43M01 Jun 2022 San Diego, California, United States

Acutus Medical

Health Care
Health Diagnostics
Medical Device
$35M27 Apr 2022 Carlsbad, California, United States

Apertura Gene Therapy

Health Care
$67M26 Apr 2022 Argyll and Bute, Scotland, United Kingdom


$38M24 Feb 2022 Bozeman, Montana, United States


Health Care
Health Diagnostics
$325M22 Feb 2022 Virginia, United States

Concerto Healthcare

Health Care
Health Diagnostics
$105M03 Feb 2022 Irvine, California, United States


Health Care
Medical Device
$126M23 Dec 2021 Guilford, Connecticut, United States

The Oncology Institute of Hope and Innovation

Health Care
Health Diagnostics
Home Health Care
$275M15 Nov 2021 Downey, California, United States
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

ARS Pharmaceuticals Raises $55M in Series D Funding

– ARS Pharmaceuticals, a San Diego CA-based pharmaceutical company, raised $55M in Series D funding.
– The round was led by SR One with participation from RA Capital Management and Deerfield Management.
– The company intends to use the funds to advance Neffy through approval, to support initial launch activities, and to evaluate it in clinical studies for additional indications.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Deerfield Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: